SCHEMBL17833010

SCHEMBL17833010

CCCCCCCCCCCCCCCCC[N+]1(C)CCCCC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.50
APOBEC3A P31941 2/20 0.50
APOBEC3G Q9HC16 2/20 0.50
KMT2A Q03164 1/20 0.50
GNAI3 P08754 1/20 0.50
GNAO1 P09471 1/20 0.50
GNAI1 P63096 1/20 0.50
BBOX1 O75936 2/20 0.47
TSHR P16473 2/20 0.46
CYP3A4 P08684 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
BLM P54132 1/20 0.46
PMP22 Q01453 1/20 0.46
KDM4E B2RXH2 1/20 0.45
CTDSP1 Q9GZU7 1/20 0.41
CHRM2 P08172 1/20 0.39
CHRM4 P08173 1/20 0.39
CHRM5 P08912 1/20 0.39
CHRM1 P11229 1/20 0.39
CHRM3 P20309 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL372979 1.00 LMNA (0.50) LMNAAPOBEC3AAPOBEC3GKMT2AGNAI3
SCHEMBL14876680 1.00 LMNA (0.50) LMNAAPOBEC3AAPOBEC3GKMT2AGNAI3
SCHEMBL372728 1.00 LMNA (0.50) LMNAAPOBEC3AAPOBEC3GKMT2AGNAI3
SCHEMBL1270131 1.00 LMNA (0.50) LMNAAPOBEC3AAPOBEC3GKMT2AGNAI3
SCHEMBL3767420 1.00 LMNA (0.50) LMNAAPOBEC3AAPOBEC3GKMT2AGNAI3
SCHEMBL2859790 1.00 LMNA (0.50) LMNAAPOBEC3AAPOBEC3GKMT2AGNAI3
SCHEMBL92719 1.00 LMNA (0.50) LMNAAPOBEC3AAPOBEC3GKMT2AGNAI3
SCHEMBL17832883 1.00 LMNA (0.50) LMNAAPOBEC3AAPOBEC3GKMT2AGNAI3
SCHEMBL3765758 1.00 LMNA (0.50) LMNAAPOBEC3AAPOBEC3GKMT2AGNAI3
SCHEMBL372390 1.00 LMNA (0.50) LMNAAPOBEC3AAPOBEC3GKMT2AGNAI3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016094226-A1 PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS GLYCOREGIMMUNE, INC. (US) 2016-06-16 WO disclosed